Mercer Global Advisors Inc. ADV Has $16.66 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mercer Global Advisors Inc. ADV reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,384 shares of the biopharmaceutical company’s stock after selling 2,389 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Regeneron Pharmaceuticals were worth $16,657,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Willner & Heller LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 15 shares during the period. OLD Second National Bank of Aurora grew its holdings in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 15 shares in the last quarter. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the period. TD Private Client Wealth LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 18 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on REGN. StockNews.com cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research note on Friday, April 25th. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $892.60.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $605.61 on Friday. The stock has a 50-day moving average price of $626.49 and a two-hundred day moving average price of $711.45. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a market capitalization of $66.21 billion, a PE ratio of 15.82, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 earnings per share. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.